Loading company…
Eindhoven-based Xeltis develops bioresorbable vascular grafts and patches for cardiovascular conditions.
Founded in 2006 by Laurent Grandidier and Martijn Cox, it sells implants to hospitals and surgeons in Europe and North America and is listed at the Series D stage. In July 2026 it raised EUR 20.5 million in venture funding led by Horizon 3 Healthcare, and the funds are planned for the aXess trial, FDA submission and manufacturing expansion.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in